Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Obesity treatments cause profits to balloon at Novo Nordisk
(Sharecast News) - Denmark's Novo Nordisk reported better-than-expected sales and earnings on Wednesday, on the back of surging demand for blockbuster weight-loss treatment Wegovy. The pharmaceutical firm reported net sales of Danish krone 232.3bn (£26.6bn) for the year to 31 December, an increase of 31%, or 36% on a constant currency basis.
Operating profits climbed 37% to DKK102.6bn, while net profits swelled 51% to DKK83.7bn.
In the fourth quarter, profits jumped 62% to DKK22bn and sales by 37% to DKK65.9, comfortably ahead of analyst expectations.
The strong performance was driven by bumper sales of diabetes and obesity treatments, in particular Ozempic and Wegovy.
Sales of Wegovy rocketed 407% to DKK31.3bn following successful launches of the treatment in the US, UK, much of northern Europe and the United Arab Emirates.
In the US, sales rose 380% following the commercial relaunch in January 2023, with demand continuing to outstrip supply.
Global sales of Ozempic, which is used to treat Type 2 diabetes, rose 60% to DKK 95.7bn.
In contrast, rare disease sales decreased by 16% to DKK17.2bn, as manufacturing output was reduced.
Lars Fruergaard Jorgensen, chief executive, said: "We are very pleased with the strong performance in 2023, reflecting that more than 40m people are now benefiting from our innovative diabetes and obesity treatments.
"Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity."
The firm acknowledged that sales growth would slow in the current year, to between 18% and 26% on a constant exchange rate basis, on the back of stiffer competition and production bottlenecks.
Operating profits were forecast to rise by between 21% and 29%.
As at 0915 GMT, shares in the Copenhagen-listed firm were up 2%.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.